Galimedix Therapeutics Establishes Scientific Advisory Board of Renowned Retina Experts as Company Prepares to Enter Phase 2 Clinical Study with GAL-101
Board consists of key opinion leaders from both clinical practice and academia with strong track records in the development of ophthalmic compoundsGalimedix is well positioned for the next phase of development of GAL-101 eye drops in dry AMD, addressing a major medical need in ophthalmologyScientific Advisory Board meeting was held to discuss Phase 2 DREAM trial, which is expected to initiate in late 2024KENSINGTON, MD / ACCESSWIRE / June 10,...
Read more








